mecasermin

{{Short description|Pharmaceutical drug}}

{{Drugbox

| Verifiedfields = changed

| Watchedfields = changed

| verifiedrevid = 462101108

| image =

| tradename = Increlex

| Drugs.com = {{drugs.com|monograph|mecasermin}}

| pregnancy_AU = B3

| pregnancy_category =

| routes_of_administration = Subcutaneous injection

| ATC_prefix = H01

| ATC_suffix = AC03

| legal_AU = S4

| legal_AU_comment = https://www.tga.gov.au/resources/auspmd/increlex {{Bare URL inline|date=August 2024}}

| legal_CA = Rx-only

| legal_CA_comment = / Schedule D{{cite web | title=Summary Basis of Decision (SBD) for Increlex | website=Health Canada | date=23 October 2014 | url=https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?linkID=SBD00524&lang=en | access-date=29 May 2022}}

| legal_UK =

| legal_US = Rx-only

| legal_US_comment = {{cite web | title=Increlex- mecasermin injection, solution | website=DailyMed | date=7 May 2020 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a8b27a1b-a611-4f91-ad22-76d4b390c3ae | access-date=30 May 2022}}

| legal_status =

| bioavailability =

| protein_bound =

| metabolism =

| elimination_half-life = 5.8 hours

| excretion =

| CAS_number_Ref = {{cascite|changed|??}}

| CAS_number = 68562-41-4

| PubChem =

| DrugBank_Ref = {{drugbankcite|changed|drugbank}}

| DrugBank = DB01277

| UNII_Ref = {{fdacite|correct|FDA}}

| UNII = 7GR9I2683O

| KEGG_Ref = {{keggcite|changed|kegg}}

| KEGG = D04870

| ChEMBL_Ref = {{ebicite|changed|EBI}}

| ChEMBL = 1201716

| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}

| ChemSpiderID = none

| synonyms = FK-780; Recombinant human insulin-like growth factor-1; rhIGF-1; Somatomedin-1

| IUPAC_name =

| C=331 | H=512 | N=94 | O=101 | S=7

}}

Mecasermin, sold under the brand name Increlex, also known as recombinant human insulin-like growth factor-1 (rhIGF-1), is a recombinant form of human insulin-like growth factor 1 (IGF-I) which is used in the long-term treatment of growth failure and short stature in children with severe primary IGF-I deficiency, for instance due to growth hormone deficiency or Laron syndrome (growth hormone insensitivity).{{cite journal | vauthors = Fintini D, Brufani C, Cappa M | title = Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency | journal = Therapeutics and Clinical Risk Management | volume = 5 | issue = 3 | pages = 553–9 | date = June 2009 | pmid = 19707272 | pmc = 2724186 | doi = 10.2147/tcrm.s6178 | doi-access = free }}{{cite web|url=https://www.drugs.com/increlex.html|title=Increlex|publisher=Drugs.com|access-date=10 January 2010}}

Mecasermin has a biological half-life of about 5.8 hours in children with severe primary IGF-1 deficiency.

A related medication is mecasermin rinfabate (brand name Iplex), which is a combination of mecasermin (rhIGF-1), insulin-like growth factor binding protein-3 (IGFBP-3), and insulin-like growth factor binding protein acid labile subunit (IGFALS) as a ternary complex.{{cite web | title = Iplex (mecasermin rinfabate [rDNA origin] injection) Package Insert | work = U.S. Food and Drug Administration | url = https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/021884s001lbl.pdf }} The complex serves to prolong the action of mecasermin in the human body; the half-life of mecasermin when provided as this complex is 13.4 hours in individuals with severe primary IGF-1 deficiency.

Mecasermin therapy has been also shown to be beneficial in other conditions not related to growth failure, including diabetes mellitus and anorexia nervosa.{{cite journal |vauthors=Keating GM |date=2008 |title=Mecasermin |journal=BioDrugs |volume=22 |issue=3 |pages=177–188 |doi=10.2165/00063030-200822030-00004 |pmid=18481900}}